Guilty as charged: B-RAF is a human oncogene

Cancer Cell

Volumn 6, Issue 4, 2004, Pages 313-319

  Garnett, Mathew J ^a   Marais, Richard ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; IMATINIB; PROTEIN INHIBITOR; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; FREQUENCY ANALYSIS; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MUTATIONAL ANALYSIS; ONCOGENE; OVARY CARCINOMA; PAPILLARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; THYROID CARCINOMA;

EID: 5444227865     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.09.022     Document Type: Review

References (45)

1. Avruch J., Khokhlatchev A., Kyriakis J.M., Luo Z., Tzivion G., Vavvas D., Zhang X.F. Ras activation of the Raf kinase. Tyrosine kinase recruitment of the MAP kinase cascade Recent Prog. Horm. Res. 56:2001;127-155
2. Bos J.L. Ras oncogenes in human cancer. Cancer Res. 49:1989;4682-4689
3. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62:2002;6997-7000
4. Busca R., Abbe P., Mantoux F., Aberdam E., Peyssonnaux C., Eychene A., Ortonne J.P., Ballotti R. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 19:2000;2900-2910
5. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature. 417:2002;949-954
6. Daya-Grosjean L., Dumaz N., Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J. Photochem. Photobiol. B. 28:1995;115-124
7. De Vita V., Hellman S., Rosenberg S. Cancer. Principles and Practice of Oncology 6th ed:2001;Lippincott, Williams and Wilkins, Philadelphia
8. Edwards R.H., Ward M.R., Wu H., Medina C.A., Brose M.S., Volpe P., Nussen-Lee S., Haupt H.M., Martin A.M., Herlyn M., et al. Absence of BRAF mutations in UV-protected mucosal melanomas. J. Med. Genet. 41:2004;270-272
9. Fabian J.R., Daar I.O., Morrison D.K. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 13:1993;7170-7179
10. Fransen K., Klintenas M., Osterstrom A., Dimberg J., Monstein H.J., Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 25:2004;527-533
11. Fukushima T., Suzuki S., Mashiko M., Ohtake T., Endo Y., Takebayashi Y., Sekikawa K., Hagiwara K., Takenoshita S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 22:2003;6455-6457
12. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880
13. Guan K.-L., Figueroa C., Brtva T.R., Zhu T., Taylor J., Barber T.D., Vojtek A.B. Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem. 275:2000;27354-27359
14. Hanks S.K., Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily. kinase (catalytic) domain structure and classification FASEB J. 9:1995;576-596
15. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63:2003;5198-5202
16. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 18:1999;813-822
17. Houben R., Becker J.C., Kappel A., Terheyden P., Brocker E.B., Goetz R., Rapp U.R. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3:2004;6
18. Iacovelli L., Capobianco L., Salvatore L., Sallese M., D'Ancona G.M., De Blasi A. Thyrotropin activates mitogen-activated protein kinase pathway in FRTL-5 by a cAMP-dependent protein kinase A-independent mechanism. Mol. Pharmacol. 60:2001;924-933
19. Ikenoue T., Hikiba Y., Kanai F., Tanaka Y., Imamura J., Imamura T., Ohta M., Ijichi H., Tateishi K., Kawakami T., et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 63:2003;8132-8137
20. Ikenoue T., Hikiba Y., Kanai F., Aragaki J., Tanaka Y., Imamura J., Imamura T., Ohta M., Ijichi H., Tateishi K., et al. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor κB pathway and cellular transformation. Cancer Res. 64:2004;3428-3435
21. Johnson L.N., Lowe E.D., Noble M.E., Owen D.J. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 430:1998;1-11
22. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., et al. B-RAF is a therapeutic target in melanoma. Oncogene. 23:2004;6292-6298
23. Kerkhoff E., Rapp U.R. High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res. 58:1996;1636-1640
24. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer. genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Res. 63:2003;1454-1457
25. Kumar R., Angelini S., Czene K., Sauroja I., Hahka-Kemppinen M., Pyrhonen S., Hemminki K. BRAF mutations in metastatic melanoma. a possible association with clinical outcome Clin. Cancer Res. 9:2003;3362-3368
26. Maldonado J.L., Fridlyand J., Patel H., Jain A.N., Busam K., Kageshita T., Ono T., Albertson D.G., Pinkel D., Bastian B.C. Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst. 95:2003;1878-1890
27. Marais R., Marshall C.J. Control of the ERK MAP kinase cascade by Ras and Raf. Parker P.J., Pawson T. Cell Signalling. 1996;101-125 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
28. Marshall C.J. Specificity of receptor tyrosine kinase signalling. transient versus sustained extracellular signal-regulated kinase activation Cell. 80:1995;179-185
29. Mason C.S., Springer C., Cooper R.G., Superti-Furga G., Marshall C.J., Marais R. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18:1999;2137-2148
30. Mercer K.E., Pritchard C.A. Raf proteins and cancer. B-Raf is identified as a mutational target Biochim. Biophys. Acta. 1653:2003;25-40
31. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:2003;859-871
32. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88:2003;5399-5404
33. Pollock P., Harper U.L., Hansen K.S., Yudt L., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33:2003;19-20
34. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis. RAF/RAS oncogenes and mismatch-repair status Nature. 418:2002;934
35. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:1997;180-186
36. Sewing A., Wiseman B., Lloyd A.C., Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol. Cell. Biol. 17:1997;5588-5597
37. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 305:2004;399-401
38. Shawver L.K., Slamon D., Ullrich A. Smart drugs. tyrosine kinase inhibitors in cancer therapy Cancer Cell. 1:2002;117-123
39. Singer G., Oldt R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., Shih I. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95:2003;484-486
40. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 116:2004;855-867
41. Wellbrock C., Ogilvie L., Hedley D., Karasarides M., Martin J., Niculescu-Duvaz D., Springer C.J., Marais R. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64:2004;2338-2342
42. Woods D., Parry D., Cherwinski H., Bosch E., Lees E., McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17:1997;5598-5611
43. Yazdi A.S., Palmedo G., Flaig M.J., Puchta U., Reckwerth A., Rutten A., Mentzel T., Hugel H., Hantschke M., Schmid-Wendtner M.H., et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J. Invest. Dermatol. 121:2003;1160-1162
44. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62:2002;6451-6455
45. Zhang B.H., Guan K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19:2000;5429-5439